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’ INTRODUCTION
Persistent organic pollutants (POPs) in the environment can
bioaccumulate and biomagnify in the foodchain.1 POPs are
consequently found in significant concentrations in adipose
tissue and blood of top predators.2 The number of reports on
levels of blood accumulative pollutants (BAP) in humans3 and
wildlife1,2 is rapidly increasing. These chemicals, such as poly-
brominated diphenyl ethers (PBDEs), polychlorinated biphenyls
(PCBs), hydroxylated PBDEs (OH-PBDEs), hydroxylated
PCBs (OH-PCBs) and other halogenated phenols (OHPs),
are known to interfere with the thyroid hormone (TH) system.4
TH-disrupting compounds may compete with thyroxine (T4)
binding to transthyretin (TTR), one of the T4-transport
proteins.4,5 Other compounds such as perfluoroalkyl substances
(PFASs) have no structural similarity with THs but have a TTR-
binding potency in the order of one-tenth of the endogenous T4.
6
TTR-binding compounds can reduce the concentrations of THs
in the blood circulation of experimental animals7 as well as in
humans8 and wildlife,9 but the lowest dose of these contaminants
causing this effect is not well established.4 Decreased TH levels
in blood might lead to subclinical hypothyroidism in adults.
Furthermore, a normal level of THs is crucial for development of
the central nervous system during gestation and for general
development in childhood.4 In wildlife there is concern that TH-
disruption may have a negative effect on fitness of top predator
species, such as the polar bear (Ursus maritimus).10
To identify known and unknown TH-disruptors in complex
environmental matrices (e.g., blood plasma), Effect-Directed Anal-
ysis (EDA) - the combined and iterative use of biological and
analytical chemical techniques to direct chemical analysis to those
compounds that actually have biological activity11 - is a promising
approach. For successful EDA studies of blood plasma a gentle,
nondestructive, nondiscriminating sample treatment is one of the
key factors to broaden the scope of EDA from abiotic to biotic
matrices.
The objective of the present study was to develop and validate a
method combining solid-phase extraction (SPE) and liquidliquid
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ABSTRACT: A sample preparation method combining solid-phase
extraction (SPE) and liquidliquid extraction (LLE) was developed to
be used in Effect-Directed Analysis (EDA) of blood plasma. Until now
such a method was not available. It can be used for extraction of a broad
range of thyroid hormone (TH)-disruptors from plasma with high
recoveries. Validation of the method using spiked cow plasma showed
good recoveries for hydroxylated polybrominated diphenyl ethers
(OH-PBDEs; 93.8 ( 19.5%), hydroxylated polychlorinated biphenyls
(OH-PCBs; 93.8( 15.5%), other halogenated phenols (OHPs; 107(
8.1%), and for short-chain (<8 C-atoms) perfluoroalkyl substances
(PFASs; 85.2 ( 24.6%). In the same extracts, the potency of the
compound classes spiked to the cow plasma to competitively bind to
transthyretin (TTR) was recovered by 84.9 ( 8.8%. Furthermore, the
SPE-LLE method efficiently removed endogenous THs from the extracts, thereby eliminating their possible contribution to the
binding assay response. The SPE-LLEmethod was applied to polar bear plasma samples to investigate its applicability in future EDA
studies focusing on TH-disrupting compounds in this top predator species that is exposed to relatively high levels of
bioaccumulating pollutants. A first screening revealed TTR-binding potency in the polar bear plasma extracts, which could be
explained for 6085% by the presence of OH-PCBs.
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extraction (LLE) for extraction of a broad range of known and
unknown TH-disrupting compounds from plasma samples. Re-
coveries of a wide selection of TH-disrupting compounds from
spiked cow plasma were chemically determined by gas and liquid
chromatography (GC and LC) coupled to mass spectrometry
(MS) and recoveries of their competitive TTR-binding activities
were biologically determined in the T4*-TTR binding assay.
5
Furthermore, the total T4 (TT4) concentration in cow plasma
before and after the extraction was measured to estimate the T4
removal capability of the SPE-LLEmethod. Extracts of cow plasma
samples spikedwithOH-PCBsandOH-PBDEswere also fractionated
using normal-phase high performance liquid chromatography
(NP-HPLC) to separate xenobiotic TH-disrupting compounds
from endogenous THs that could affect the bioassay results.
Finally, two polar bear plasma extracts were prepared using the
validated SPE-LLE method and tested in the T4*-TTR binding
assay to demonstrate the applicability of the developed sample
preparation method in further EDA studies.
’MATERIALS AND METHODS
Plasma Samples and Spiking Mixtures. Cow plasma was
used for method validation because no or only very low levels of
Table 1. Overview of the Six Spiking Mixtures Used to Spike Cow Plasma Samplesk











1. OH-PCBs 4-OH-CB 107a 4-hydroxy-2,3,30 ,40 ,5-pentachlorobiphenyl n.a. 342.44 3.4  102 3.5 this study
4-OH-CB 118b 4-hydroxy-2,30 ,4,40 ,5-pentachlorobiphenyl n.a. 342.44 3.4  102 4.1 this study
40-OH-CB 130b 40-hydroxy-2,20 ,3,30 ,4,50-hexachlorobiphenyl n.a. 376.88 3.1  102 3.7 this study
4-OH-CB 187a 4-hydroxy-2,20 ,3,40 ,5,50 ,6-heptachlorobiphenyl n.a. 411.33 2.8  102 4.0 this study
2. OH-PBDEs 20-OH-BDE-66b 20-hydroxy-2,30 ,4,40-tetrabromodiphenylether n.a. 501.8 4.5  102 6.5  101 Hamers et al., 200812
3-OH-BDE-47b 3-hydroxy-2,20 ,4,40-tetrabromodiphenylether n.a. 501.8 4.6  102 4.0 Hamers et al., 200812
40OH-BDE-49b 40-hydroxy-2,20 ,4,50-tetrabromodiphenylether n.a. 501.8 3.3  102 3.5 Hamers et al., 200812
4-OH-BDE-47b 4-hydroxy-2,20 ,3,40-tetrabromodiphenylether n.a. 501.8 4.6  102 3.9  101 Hamers et al., 200812
5-OH-BDE-47b 5-hydroxy-2,20 ,4,40-tetrabromodiphenylether n.a. 501.8 3.0  102 3.0 Hamers et al., 200812
3. PCBs and PBDEs BDE 28c 2,4,40-tribromodiphenyl ether 41318-75-6 485.8 3.1  102 - Hamers et al., 200613
BDE 47c 2,20 ,4,40-tetrabromodiphenyl ether 5436-43-1 485.8 3.4  102 2.2  103 Hamers et al., 200613
BDE 49c 2,20 ,4,50-tetrabromodiphenyl ether 446255-38-5 485.8 3.1  102 2.2  103 Hamers et al., 200613
BDE 100c 2,20 ,4,40 ,6-pentabromodiphenyl ether 32534-81-9 564.7 3.1  102 - Hamers et al., 200613
PCB 138d 2,20 ,3,4,40 ,50-hexachlorobiphenyl 35065-28-2 360.9 1.3  101 <3.8  103 Hamers et al., 201114
PCB 153d 2,20 ,4,40 ,5,50-hexachlorobipenyl 35065-27-1 360.9 1.3  101 <3.8  103 Hamers et al., 201114
PCB 170d 2,20 ,3,30 ,4,40 ,5-heptachlorobiphenyl 35065-30-6 395.3 1.2  101 <3.8  103 Hamers et al., 201114
PCB 180d 2,20 ,3,4,40 ,5,50-heptachlorobiphenyl 39635-31-9 395.3 1.2  101 <3.8  103 Hamers et al., 201114
4. PFASs PFBAe perfluorobutyric acid 375-22-4 214.0 6.1  102 n.d. Weiss et al., 20096
PFPeAf perfluoro-n-pentanoic acid 2706-90-3 264.0 5.1  102 1.8  101 this study
PFHxAf perfluorohexanoic acid 307-24-4 314.0 4.2  102 7.0  103 Weiss et al., 20096
PFHpAe perfluoroheptanoic acid 375-85-9 364.1 3.5  102 3.9  102 Weiss et al., 20096
PFOAf perfluorooctanoic acid 335-67-1 414.0 3.1  102 6.4  102 Weiss et al., 20096
PFNAg perfluorononanoic acid 375-95-1 464.0 2.8  102 2.2  102 Weiss et al., 20096
PFDcAe perfluorodecanoic acid 335-76-2 514.0 2.8  102 7.0  103 Weiss et al., 20096
PFUnAg perfluoroundecanoic acid 2058-94-8 563.9 2.3  102 3.0  103 Weiss et al., 20096
PFDoAg perfluorododecanoic acid 307-55-1 614.0 2.2  102 1.0  103 Weiss et al., 20096
PFTrAe perfluorotridecanoic acid 72629-94-8 664.0 1.9  102 6.4  102 this study
PFTdAe perfluorotetradecanoic acid 376-06-7 713.9 1.8  102 2.0  103 Weiss et al., 20096
PFBSg perfluorobutane sulfonate 2795-39-3 300.0 3.8  102 3.0  103 Weiss et al., 20096
PFHxSh perfluorohexane sulfonate 3871-99-6 400.0 3.2  102 8.5  102 Weiss et al., 20096
6:2 FTSi 6:2 fluorotelomersulfonate 27619-97-2 427.0 2.5  102 n.d. this study
PFOSh perfluorooctane sulfonate 2795-39-3 500.0 2.5  102 6.5  102 Weiss et al., 20096
PFOSAi perfluorooctanesulfonamide 754-91-6 499.2 2.7  102 1.0  102 Weiss et al., 20096
5. OHPs 2.4.6-TCPj 2,4,6-trichlorophenol 88-06-2 197.5 4.7  101 3.3  101 Van den Berg et al., 199015
2.4.6-TBPj 2,4,6-tribromophenol 118-79-6 330.8 2.9  101 3.0 this study
PCPg pentachlorophenol 87-86-5 266.3 3.4  101 1.7 Van den Berg et al., 199015
triclosang 5-chloro-2-(2,4-dichlorophenoxy)phenol 3380-34-5 289.5 3.5  101 1.0  102 Crofton et al., 200718
6. Combined mixtureOH-PCBs/OH-PBDEs/OHPs (The final concentration of the individual compounds in the combined mixture was the same as in the mixtures 1, 2, and 5,
respectively.)
aGreyhound (Birkenhead, UK). b Synthesized at Stockholm University by Prof. Dr. Åke Bergman. cChiron (Trondheim, Norway). dULTRA Scientific
(N. Kingstown, USA). eABCRGmbH&Co (Karlsruhe, Germany). fAcros Organics (Geel, Belgium). g Sigma (Zwijndrecht, The Netherlands). h Fluka
(Zwijndrecht, The Netherlands). iWellington (Guelph, Canada). jRiedel de Ha€en (Seelze, Germany). kThe combined mixture did not contain PCBs/
PBDEs (mixture 3) and PFASs (mixture 4). The spiking level in plasma indicates the concentration of the individual compounds.
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contaminants were expected in this type of plasma compared to
plasma from top predators, such as polar bears. Polar bear blood
samples were collected from two adult (8 and 9 year old) female
bears at Svalbard (Norway) in April 2008. Two mL of each
plasma sample was extracted and tested in the radioligand T4*-
TTR binding assay. These samples were selected based on their
moderate TT4 level (8 and 20 nM, respectively), high plasma
lipid levels (1.5% for both), and knowledge of the plasma
OH-PCB levels as determined within a much larger study
(BearHealth, Web site: http://biologi.no/bearhealth-eng.htm).
Further information on cow plasma preparation and on the
sampling, extraction, and chemical analysis of the polar bear
samples can be found in the Supporting Information.
Spiking mixtures were prepared of well-known classes of TH-
disrupting compounds, such as OH-PCBs, OH-PBDEs, and
OHPs in hexane (J.T. Baker, The Netherlands) and PFASs in
methanol (MeOH; J.T. Baker). In addition, spiking mixtures of
the parent PCB and PBDE compounds were prepared in hexane.
Three mL of cow plasma was spiked in a final concentration
range of 0.0180.47 μM with 30 μL of the different spiking
mixtures. The final spiking concentration range was determined
based on the environmentally relevant concentrations and on the
analytical detection limits of the spiking compounds. In order to
better mimic environmental circumstances (e.g., that BAPs
might bind to blood plasma proteins) a low spiking volume
(30 μL) was used to avoid direct protein precipitation by the
organic solvent of the spiking mixtures. The PFAS mixture and
the PFAS-spiked plasma samples were stored in polypropylene
tubes to avoid interaction with glass surfaces. An overview of the
individual test compounds, the mixtures and the concentrations
of the individual compounds in the blood plasma after spiking is
given in Table 1. Spiked cow plasma samples, cow plasma blanks
(3 mL), and procedure blanks (3 mL HPLC-grade water) were
prepared in triplicate, whirl-mixed, and placed in the refrigerator
(at 4 C) for overnight equilibration to enable the formation of
possible bindings between the TH-disruptors and plasma proteins.
To test the influence of the sample matrix on the recoveries, an
additional spiking experiment was performedwith 3mL ofHPLC-
grade water that was spiked with 30 μL of the OH-PBDEmixture.
Sample Preparation.An overview of the experimental design
of the validation study is shown in Figure 1. The sample
preparation method consists of four steps: protein denaturation,
SPE, LLE, and NP-HPLC fractionation.
Protein Denaturation. To denaturate plasma proteins, formic
acid (HCOOH, 99% v/v; Sigma) in 2-propanol (Sigma) (4:1, v/v)
was added in a 1:1 (v/v) ratio to 3 mL of procedure blanks, spiked
andblank cowplasmas, and to 2mLof polar bear plasmas following
themethod described byThomsen et al.3 withminormodifications.
The samples were whirl-mixed, sonicated in an ultrasonic bath for
10 min, and stored in the dark for 50 min at room temperature.
Subsequently, 3 mL of water/2-propanol (4:1, v/v) was added to
each sample (2 mL to the polar bear plasma), and the resulting
mixture was sonicated for another 10 min. Finally, to reduce the
influence of the organic solvent on the SPE procedure, the samples
were diluted with water until the organic solvent percentage (iso-
propanol and solvent of the spiking mixture) was less than 5%.
Typically, the total volume before SPE was 25 mL. The obtained
plasma samples were clear and required no centrifugation step for
pellet separation before extraction.
Solid-Phase Extraction (SPE) and Clean Up. The Oasis MCX
cartridge (150 mg, 6 mL) was selected for this study, because
highest chemically determined recoveries of TH-disrupting
compounds was obtained for this cartridge in a pilot experiment
comparing seven different cartridges (Supporting Information).
Oasis MCX cartridges were conditioned with MeOH (3 mL) and
equilibrated with water (3 mL) before the treated plasma samples
were loaded. Solvents and samples were passed through the
cartridges dropwise. The cartridges were washed with water con-
taining 1.8% HCOOH (3 mL). After the washing step the SPE
sorbentmaterial was dried completely before elution. The adsorbed
compounds were eluted from the MCX cartridges with 4 
0.75 mL MeOH (elution 1, E1) followed by 4  0.75 mL MeOH
containing 5% ammonium hydroxide (NH4OH; Fluka, The
Netherlands) (elution2,E2).Vacuumwasonly used after thewashing
step, before elution. The SPE procedure is summarized in Figure 1.
LiquidLiquid Extraction (LLE). Using LLE, all E1 and E2
fractions were transferred into hexane that was more suitable for
further analysis, except for the extracts of the plasma spiked with
PFASs. Of the E1 and E2 fractions of these extracts, 50% was kept
in MeOH, since the PFASs were analyzed on a triple quadrupole
liquid chromatography electrospray ionization tandem mass
spectrometer (LC-ESI-MS/MS, see Chemical Validation) using
a MeOH:water (1:1, v/v) mobile phase. For LLE, the E1 and E2
fractions were transferred to 20 mL glass tubes with screw caps,
and 57 mL of 4% phosphoric acid (H3PO4; Fluka) and 2mL of
hexane were added. The addition of H3PO4 improved the
extraction of the hydroxylated compounds (data not shown).
Subsequently, the samples were vortexed (1 min) and centri-
fuged (3 min; 1500 rpm). The upper hexane layers containing
the compounds of interest were carefully separated and collected.
The hexane fractions were then loaded onto a Pasteur pipet filled
with dried sodium sulfate (Na2SO4, Promochem, Germany) to
remove water, if present. The whole procedure, starting with the
addition of 2 mL of hexane, was repeated another two times. For
each fraction, the hexane layers were combined, and the extracts
E1, hex and E2, hex were evaporated under nitrogen until a volume
of 0.5 mL.
Normal-Phase High Performance Liquid Chromatography
(NP-HPLC). To avoid interference of endogenous THs with the
bioassay measurements, they were separated from the plasma
extracts via NP-HPLC fractionation. Half of both the E1, hex and
E2, hex fractions of the plasma spiked with OH-PCBs and OH-
PBDEs was loaded on a μPorasil NP-HPLC column (7.8 mm ID,
300mm) packedwith 10-μmμPorasil (Waters Assoc., USA), using
a mobile phase gradient of hexane, dichloromethane (DCM;
Promochem), and acetonitrile (ACN; J.T. Baker) at a flow-rate
of 5 mL/min, as described before.17 The 040 min (F1) and
4149 min (F2) NP-HPLC fractions were collected, resulting in
the fractions E1F1, E1F2, E2F1, and E2F2 (Figure 1). In these
fractions recoveries (chemical analysis) and competitive TTR-
binding activities (T4*-TTR assay) were determined. The analytes
were expected to elute from the column in the firstHPLC-fractions,
the endogenous hormones in the second.17 The other half of the
extracts was kept unfractionated to compare the chemically deter-
mined recoveries and the biological activities of the fractionated and
nonfractionated extracts. Fractionated and nonfractionated extracts
were equally divided into two parts: half was exchanged into 50 μL
of DMSO (Acros, Belgium) for testing in the T4*-TTR binding
assay and half was kept in 50 μL of hexane for chemical analysis.
Endogenous Total T4 Levels. To check the capacity of the SPE
procedure to remove endogenous T4, TT4 concentration was
measured in the original cow plasma and in its E1 fraction at the
Academic Medical Center (AMC) Amsterdam using a radio-
immunoassay, according to their validated protocol. The E1
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fraction in MeOH was evaporated under nitrogen to almost
dryness and dissolved in bovine serum (Gibco, The Nether-
lands) stripped with T500dextran and activated charcoal. As a
control, TT4 levels were also determined in stripped serum only.
The initial TT4 concentration in polar bear plasma was measured
previously within the BearHealth project using a radioimmu-
noassay according to Braathen et al.9
Chemical Validation. For chemical analysis, internal stan-
dards are generally used to evaluate the analytical method
performance, as for instance done by Thomsen et al.3 However,
to determine recoveries in biota extracts in bioassays or in an
EDA setup, internal standards cannot be used due to their
possible influence on the bioassay results. Thus, target com-
pounds were quantified in all cases by external standard calibra-
tion by the same mixtures used for spiking.
Chemically determined recoveries of OH-PBDEs in the
extracts of the spiked plasma were measured by gas chromato-
graphymass spectrometry (GC-MS) operated with electron
capture negative ionization (ECNI) in the selected ion mode
(SIM). Recoveries of OHPs were determined by GC-electron
impact (EI)-MS operated in both SIM and full scan mode
(scanning mass range: 50400 m/z). The analysis of PCBs,
PBDEs, and OH-PCBs was performed by GC with micro
electron capture detection (μECD). PFASs were analyzed by
LC-ESI-MS/MS. For more detailed method descriptions see the
Supporting Information.
Bioassay Validation. To assess the competition between the
TH-disrupting compounds in the extracts and the reference T4
(Sigma) for binding to the T4-transporting protein TTR
(Sigma), the extracts were tested in the radioligand T4*-TTR
binding assay according to Lans et al.5 with modifications as
described by Hamers et al.13 and Weiss et al.6 The spiking
mixtures were also tested directly in the assay to determine their
activities in the absence of any sample matrix. The spiking
mixtures, all fractions of the procedure blanks and of the extracts
of the spiked and nonspiked plasma were tested in the bioassay in
a dilution series (131030100). The extract of the plasma
spiked with the combined mixture was tested in more dilutions
(13103060100300) due to its expected higher activ-
ity. Doseresponse curves of the reference compound T4 were
fitted using a sigmoidal fit with variable slope in GraphPad Prism
(version 5.01 for Windows, GraphPad Software). TTR-binding
activities of the extracts were expressed as T4 equivalent (T4-Eq)
concentrations. For interpolation into the T4 doseresponse
curve (Figure 2A), the most diluted sample was used that caused
a response in the 2050% inhibition window.
To calculate the theoretically expected TTR-binding activity
of the spiking compounds (in terms of T4-Eq concentrations),
the concentration of each spiked compound was multiplied by its
relative potency factor (REP-factor). The expected total TTR-
binding activity of the extract was calculated by summation of the
TTR-binding activities calculated for the individual compounds
in the mixture. Finally, recoveries were determined by comparing
the actually measured activity of the spiked plasma extracts to i)
the calculated total activity of the spiked compounds and ii) to
the actually measured activities of the spiking mixtures (after
transfer to DMSO). Spiking concentrations and REP factors
of the test compounds are listed in Table 1. REP factors were
collected from previously published studies or were deter-
mined in the T4*-TTR binding assay in this study (Table 1 and
4, Figure 2B). REP-factors were determined by the 50%
inhibition concentrations (IC50) of the reference compound
(T4) and of the test compound: REP-factortest comp= IC50T4/
IC50test comp.
Similarly, the theoretically expected activity of the polar bear
plasma extract in the T4*-TTR binding assay was calculated
based on the measured OH-PCB levels and the REP-factors
listed in Table 4.
Figure 1. Complete experimental scheme of the SPE-LLE-HPLC extraction and cleanupmethod evaluation onOasis MCX (150mg/6mL) cartridges.
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’RESULTS AND DISCUSSION
Validation. Recoveries Determined by Chemical Analysis. For
the plasma samples spiked with OH-PCBs and the OH-PBDEs,
both the fractions E1, hex and E2, hex and their subfractions after
NP fractionation (E1F1, E1F2, E2F1, and E2F2) were chemically
analyzed to determine the recoveries of the individual com-
pounds. This first recovery screening revealed that the spiked
compounds eluted mainly in the first SPE fraction (E1, hex), while
no spiked compounds or only very small amounts were detected
in the second fraction (E2, hex). Therefore, the E2 fractions were
not further analyzed. After NP-HPLC fractionation, OH-PBDEs
were found in subfraction E1F1, whereas OH-PCBs were de-
tectedmainly in the E1F2 subfraction, where also the endogenous
THs were expected.17 Because relevant analytes were found in
both the E1F1 and E1F2 subfractions and the TT4 concentration
in the plasma extract was too low to interfere with the radioligand
T4*-TTR bioassay (see below), further chemical analyses and
bioassay measurements of other samples were restricted to
fraction E1, hex without NP-HPLC fractionation.
After SPE-LLE, the test compounds in fraction E1, hex showed
average ((SD) recoveries of 107((8.1)% for the OHPs,
93.8((15.5)% for the OH-PCBs, and 93.8((19.5)% for the
OH-PBDEs (Table 2).
For parent PCBs and PBDEs low recoveries were found
(∼30%, E1, hex, Table 2). Thomsen et al.3 reported recoveries
of 64108% for the same PCBs and PBDEs in spiked serum
extracted by Oasis HLB through reversed-phase hydrophobic
interaction. In our cartridge selection experiment the same type
of HLB cartridge was tested, but this material did not provide
recoveries above 30% for these compounds (Table S2, Support-
ing Information). Since the hydroxylated metabolites of PCBs
and PBDEs have remarkably stronger TTR-binding affinity than
their parent compounds,4,12,18 no further effort was made to
improve recovery of the parent compounds.
The recoveries of the PFASs in E1 (for which no LLE was done
prior to chemical analysis) decreased with carbon atom chain
length from 115% to 2%, with acceptable recoveries 85.2((24.6)%
for themost potent, short chain (<8C-atoms) PFASs, independent
of the type of their polar group (Table 2).
Biologically Determined Recoveries. In the TTR-assay, all
extracts of plasma spiked with the different compound classes
showed activity in accordance with the chemically determined
Figure 2. Competitive TTR-binding potency A) of the T4 reference curve in different experiments, B) of the individual OH-PCB standards for REP-
value determination, C) E1, hex, E1F1 and E1F2 (sub)fractions of plasma spiked with OH-PCBs, D) E1, hex, E1F1 and E1F2 (sub)fractions of plasma spiked
with OH-PBDEs, E) fraction E1, hex of plasma spiked with OHPs and the combinedmixture, F) fraction E1, hex of one of the polar bear plasma extracts. In
A-B) the logarithmically scaled X-axes show the concentration of T4 and OH-PCBs in the assay (nM) and in CF) the logarithmically scaled X-axes
show the relative concentration of T4 and the analytes in the extracts based on the dilution of the extracts. The undiluted extracts correspond to 1. On the
Y-axis of each figure the percentage (%) of binding of T4* to TTR is indicated.
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recoveries and with the calculated and measured activities of the
spiking mixtures (Tables 2 and 3).
For extracts of plasma samples spiked with OH-PCBs,
TTR-binding activities were mainly found in the E1, hex
fraction, especially in its second subfraction E1F2 (Figure 2
C). An activity of 0.52 μM T4-Eq was found in the E1, hex,
which is in good agreement with the calculated activity
(0.50 μM T4-Eq; 104% recovery) and with the measured
activity in the spiking mixtures (0.58 μMT4-Eq; 90% recovery)
(Table 3).
For extracts of plasma samples spiked with OH-PBDEs, TTR-
binding activities were also found in the fraction E1, hex, but in its
first HPLC fraction E1F1 (Figure 2D). The measured activity in
the E1 (0.41 μMT4-Eq) was in line with the calculated (0.48 μM
T4-Eq) and measured (0.49 μM T4-Eq) activities, resulting in
recoveries >84% (Table 3).
The activities found in the extracts of plasma samples spiked
with the OHPs (1.51 μM T4-Eq) were in accordance with the
measured activity in the spikingmixture (77% recovery) and with
the calculated activity (82%; Table 3, Figure 2E). The extracts of
Table 2. Chemical Recoveries (%(SD) of the Spiking Compounds Determined in the Fraction E1, hex of the Spiked Cow Plasma
after SPE (n = 3) by GC-MS, GC-μECD, and LC-MS/MS
GC-MS, GC-μECD, % ( SD LC-MS/MS % ( SD chain length polar group
2,4,5-TCP 113 ( 9.8 PFBA 60 ( 14.9 4 acid
2,4,6-TBP 110 ( 5.4 PFPeA 95 ( 20.1 5
PCP 95 ( 3.8 PFHxA 111 ( 1.6 6
triclosan 110 ( 9.2 PFHpA 104 ( 7.0 7
Average 107 ( 8.1 PFOA 83 ( 11.8 8
4-OHCB 118 97 ( 2.1 PFNA 51 ( 9.1 9
4-OHCB 107 105 ( 11.3 PFDcA 24 ( 3.8 10
40OH-CB 130 102 ( 8.7 PFUnA 12 ( 1.0 11
4-OHCB 187 71 ( 1.5 PFDoA 6 ( 0.2 12
Average 93.8 ( 15.5 PFTrA 3 ( 0.2 13
BDE 28 32 ( 7 PFTdA 2 ( 0.2 14
PCB 153 29 ( 7 Average 50 ( 42.9
PCB 138 30 ( 7 PFBS 115 ( 15.1 4 sulfonate
BDE 49 30 ( 7 PFHxS 87 ( 11.8 6
BDE 47 30 ( 7 PFOS 33 ( 4.4 8
PCB 180 29 ( 7 THPFOS 87 ( 9.6 8
PCB 170 30 ( 7 Average 81 ( 34.3
BDE 100 26 ( 6 PFOSA 77 ( 10.0 8 sulfonamide
Average 30 ( 1.7 Average short chain PFASs (<8) 85 ( 24.6
40OH-BDE49 120 ( 19.5
5-OH-BDE47 102 ( 19.3
4-OH-BDE47 98 ( 18.8
3-OH-BDE47 76 ( 9.8
20OH-BDE66 73 ( 7.1
Average 93.8 ( 19.5
Table 3. Overview of the TTR-Binding Activities in Extracts of Spiked Plasma (Fraction E1, hex; Oasis MCX) Measured in the
Radioligand T4*-TTR Binding Assay
d
measured activity in extracts
of spiked plasma (n = 3)
(μM T4-Eq in plasma) average ( SD
measured activity in the










OH-PCBs 0.52 ( 0.02 0.58 0.50 90 104
OH-PBDEs 0.41 ( 0.03 0.49 0.48 84 85
PCBs and PBDEs n.d. n.d. 0.003a - -
PFASs n.d. n.d. 0.013a - -
OHPs 1.51 ( 0.05 1.97 1.61 77 82
combined mixture 2.05 ( 0.08 2.62 2.59 78 79
aThese values are below the Limit of Detection (LOD), which is 0.016 μMT4-Eq (∼20% T4* binding to TTR). bThe spiking mixture was measured in
the assay after transfer into DMSO. cCalculated activities are determined based on the T4 REP-factors of the spiking compounds and their actual
concentration in the spiked plasma. dResults are expressed in μMT4-Eq in plasma and compared to the measured activity in the spiking mixtures and to
the calculated activities as recoveries (%). n.d., not detected; “-“, not calculated.
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plasma spiked with the combined mixture of OH-PCBs, OH-
PBDEs, and OHPs showed an activity of 2.05 μMT4-Eq, in good
agreement with the measured activity in the spiking mixture and
with the calculated activity (>78% recovery; Table 3, Figure 2E).
PCBs, PBDEs, and PFASs are less potent TH-disruptors than
OH-PCBs, OH-PBDEs, and OHPs and consequently also have
lower REP values (Table 1). The calculated total potencies for
the extracts of the plasmas spiked with both PCBs and PBDEs
(3 nM T4-Eq) and with PFASs (10 nM T4-Eq) were below 16
nM T4-Eq, which is the limit of detection (LOD) in the assay.
Consequently, no activity was detected in the extracts of plasma
spiked with PCBs, PBDEs, and PFASs (Table 3).
All (sub)fractions of the blanks were tested for competitive
TTR-binding activity. Neither the procedure blanks nor the
plasma blanks showed any activity. In the extract of the water
spiked with OH-PBDEs, a similar activity (0.40 μM T4-Eq) was
found as in extract of the plasma spiked with the OH-PBDEs
(0.41 μM T4-Eq), indicating that the eventually remaining
sample matrix constituents do not suppress or enhance the
TTR-binding activities of the spiked compounds in the plasma
extracts.
Endogenous TT4 Levels. The presence of endogenous hor-
mones in biota extracts may interfere with the measurement of
endocrine disrupting compounds in in vitro bioassays.17,19
Therefore, NP-HPLC fractionation was initially used to separate
endogenous hormones from POPs in biota extracts as was
previously done in studies on estrogens in blood matrices20 and
androgens and THs in fish tissues.17 The NP-HPLC elution
profile of the spiking compounds (data not shown) revealed that
OH-PCBs eluted in the same subfraction (E1F2) as the endogen-
ous THs.17 However, after SPE about 95% of the initial TT4
concentration (65 nM)was removed from the cow plasma. Taking
all the concentration and dilution steps in the T4*-TTR binding
assay protocol into account, the remaining 3 nMTT4, determined
in the E1 fraction, corresponds to 5.6 nM T4-Eq in the assay.
According to the T4 calibration curve, covering a concentration
range of 01024 nM T4 (Figure 2A), this concentration was
below 16 nMT4-Eq, which is the LOD in the assay and too low to
influence the measured activities in extracts of the spiked samples.
In the polar bear plasma, even lower initial TT4 concentrations
(8 and 20 nM, respectively) were measured, again indicating no
influence on the bioassay result. Therefore, we did not apply
further NP-HPLC fractionation for TH removal from the extracts
of other spiked cow plasma samples or nonspiked polar bear
plasma samples.
Assuming that (95% of plasma TT4 is removed during the
SPE procedure, TT4 levels for e.g., monkey, seal, fish, and
dolphin were taken from the literature,2124 and their possible
influence on the assay was calculated when extracting a 3 mL
sample (the sample volume for which the developed method was
validated). For all studied species, the calculated T4-Eqs were
already below the lowest T4 level (16 nM) that caused an effect in
the 3-fold diluted extracts (Table 5). So, further dilution will lead
to an even lower T4 level in the extracts with no influence on the
bioassay results. This indicates that the contribution of endo-
genous T4 does not lead to overestimation of the measured TTR-
binding activity in plasma extracts from different species, which
emphasizes the broad scope of the SPE-LLE method and its
suitability for inclusion in EDA strategies.
Polar Bear Plasma. The SPE-LLE method successfully ex-
tracted the biologically active compounds present in the polar
bear plasma samples and the activities, known to be partly caused
by a suite of chemically determined OH-PCBs, could be mea-
sured in the T4*-TTR binding assay. This is in accordance with a
previous study that showed that in polar bear plasma, 4-OH-
CB107 had a high binding affinity to TTR.25 In the first polar
bear plasma extract, the calculated TTR-binding activity caused
by the OH-PCBs (1.1 μM T4-Eq) could explain 85% of the
actually measured TTR-binding activity (1.3 μM T4-Eq). In the
Table 4. Measured and Calculated T4-Eq of the Two Polar
Bear Plasma Extractsa













4-OH-CB107 3.5 10.3 36.1 5.1 17.9
4-OH-CB146 3.5 70.4 246.4 73.5 257.3
30-OH-CB138 3.3 2.0 6.6 1.0 3.3
40-OH-CB130 3.7 0.5 1.9 0.3 1.1
3-OH-CB180 1.9 1.9 3.6 1.1 2.1
40-OH-CB172 3.8 33.2 126.2 42.1 160.0
4-OH-CB187 4.0 117.6 470.4 123.0 492.9
calculated activity 1.1 μM 0.9 μM
measured activity 1.3 μM 1.5 μM
% T4-Eq explained by OH-PCBs 85% 60%
aThe calculated activity is determined based on measured OH-PCBs
levels and T4 REP-factors.
Table 5. Total T4 Levels (nM) Measured in Plasma of Different Species and Their Corresponding Highest T4-Concentration in
the Radioligand T4*-TTR Binding Assay, under Similar Extraction and Test Conditions As Used in the Present Study
a
TT4 (nM) in plasma reference
T4 (nM) in T4*-TTR binding assay
(3-times diluted extract)
cow (n = 1) 65 this study 1.9
polar bear (n = 2) 820 this study 0.250.6
human (not indicated) 66181 Azezli et al., 200721 2.15.6
seal (n = 1) 2.816.3 own unpublished data 0.030.17
sea bream (n = 1) 43 Morgado et al., 200722 1.3
dolphin (n = 72) 109311 Aubin et al., 199623 3.49.7
Rhesus monkey (n = 5) 80112 Sawhney et al., 197824 2.53.5
lowest level of thyroxine (T4) in the assay causing effect: 16 nM
aA 3 mL plasma sample was reduced to a 40 μL extract in DMSO; diluted 40-times in the assay; 5% recovery of T4 was expected. These calculated
concentrations can be compared to the lowest level of T4 causing effect in the assay (Figure 2A).
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second extract, the calculated activity (0.9 μM T4-Eq) could
explain 60% of the measured activity (1.5 μM T4-Eq). The
measured activities in the polar bear plasma extracts (E1, hex)
were higher than the expected activities based on calculations
using the OH-PCB REP values and the measured ∑OH-PCB
concentrations (Table 4). This might indicate the presence of
other TH-disrupting compounds.
Method Applicability. The good (71120%) recoveries
determined by chemical analysis for various potent TH-
disruptors (OH-PCBs, OH-PBDEs, OHPs, and short-chain
PFASs except PFBA) in combination with good recoveries
(77104%) determined in extracts of plasma spiked with these
compounds in the bioassay demonstrate the applicability of
the developed plasma sample preparation method in e.g., an
EDA study.
The relative standard deviations (RSDs (%)) obtained for the
chemically analyzed recoveries of the different classes of com-
pounds ranged from 1.4 to 24.8%, while for bioassay measure-
ments RSDs of 3.3 to 8.3% were obtained.
After the chemical and biological validation of the SPE-LLE
plasma sample preparation method and a pilot study on two
polar bear plasma samples, a larger number of polar bear plasma
samples (n = 30) have been extracted in collaboration with the
Norwegian University of Science and Technology (NTNU), in the
framework of the BearHealth-project. Three polar bear plasma
samples showing a combination of high competitive TTR-binding
activity in the TTR assay with low levels of target analyzed TH-
disrupting compounds were selected for further studies to identify
the compounds causing the unexplained TTR-binding activities in
the samples. This work is currently carried out in a study design
based on EDA, using high resolution mass spectrometry to identify
the unknown TH-disrupting compounds.
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